Aratana Therapeutics Inc (PETX) Announces Earnings Results

Aratana Therapeutics Inc (NASDAQ:PETX) announced its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.34) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.34). The company had revenue of $3.80 million during the quarter, compared to analysts’ expectations of $3.05 million. Aratana Therapeutics had a negative return on equity of 19.87% and a negative net margin of 60.32%. Aratana Therapeutics’s revenue was up 2135.3% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.52) EPS.

Shares of Aratana Therapeutics (NASDAQ:PETX) traded up 2.07% during mid-day trading on Friday, hitting $5.92. The stock had a trading volume of 186,133 shares. Aratana Therapeutics has a 1-year low of $4.97 and a 1-year high of $10.73. The firm’s market capitalization is $224.71 million. The stock’s 50-day moving average is $5.90 and its 200 day moving average is $6.82.

Earnings History for Aratana Therapeutics (NASDAQ:PETX)

ILLEGAL ACTIVITY NOTICE: “Aratana Therapeutics Inc (PETX) Announces Earnings Results” was published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/05/19/aratana-therapeutics-inc-petx-announces-quarterly-earnings-results-hits-estimates-updated.html.

A number of brokerages have weighed in on PETX. William Blair reiterated an “outperform” rating on shares of Aratana Therapeutics in a report on Thursday, February 9th. Stifel Nicolaus decreased their price target on Aratana Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a report on Wednesday, May 10th. Jefferies Group LLC decreased their price target on Aratana Therapeutics to $8.00 in a report on Thursday, March 16th. Finally, Zacks Investment Research upgraded Aratana Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, March 1st. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. Aratana Therapeutics currently has an average rating of “Buy” and an average target price of $10.08.

In other news, insider Peter Steven St sold 50,000 shares of the business’s stock in a transaction dated Monday, April 17th. The stock was sold at an average price of $5.54, for a total transaction of $277,000.00. Following the completion of the sale, the insider now owns 582,693 shares in the company, valued at approximately $3,228,119.22. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.70% of the stock is currently owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in the company. Redmond Asset Management LLC boosted its position in Aratana Therapeutics by 0.4% in the fourth quarter. Redmond Asset Management LLC now owns 53,887 shares of the biopharmaceutical company’s stock worth $387,000 after buying an additional 215 shares in the last quarter. American International Group Inc. boosted its position in Aratana Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 20,534 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 1,354 shares in the last quarter. Baird Financial Group Inc. boosted its position in Aratana Therapeutics by 5.7% in the fourth quarter. Baird Financial Group Inc. now owns 30,878 shares of the biopharmaceutical company’s stock worth $222,000 after buying an additional 1,659 shares in the last quarter. Cadence Capital Management LLC boosted its position in Aratana Therapeutics by 2.6% in the fourth quarter. Cadence Capital Management LLC now owns 108,420 shares of the biopharmaceutical company’s stock worth $778,000 after buying an additional 2,745 shares in the last quarter. Finally, A.R.T. Advisors LLC boosted its position in Aratana Therapeutics by 19.3% in the fourth quarter. A.R.T. Advisors LLC now owns 17,900 shares of the biopharmaceutical company’s stock worth $128,000 after buying an additional 2,900 shares in the last quarter. Hedge funds and other institutional investors own 75.44% of the company’s stock.

Aratana Therapeutics Company Profile

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

5 Day Chart for NASDAQ:PETX

Receive News & Ratings for Aratana Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply